Frenova Renal Research

What Frenova Renal Research does

Frenova Renal Research is a global Site Management Organization (SMO) and wholly owned subsidiary of Fresenius Medical Care Holdings, Inc., operating from Waltham, Massachusetts. The company manages and executes third-party clinical trials on behalf of pharmaceutical and biotech sponsors, focused on cardio-kidney-metabolic (CKM) therapeutic areas including chronic kidney disease (CKD), end-stage kidney disease (ESKD), and adjacent cardiovascular and metabolic conditions. Its core competitive lever is structural access to Fresenius Medical Care's network of 3,675 dialysis clinics treating approximately 299,000 patients worldwide, supplemented by partner nephrology practices that feed the F1RST UP® U.S. site network and Global Network Sites in Europe, Latin America, and other regions.

Frenova operates three interconnected service lines: Site Management (with technology-assisted screening and enrollment, a single point of contact clinical project management model, and rapid feasibility-to-enrollment workflows), Data Analytics & Licensing (providing access to a longitudinal patient database covering more than 2 million patients over 25+ years for real-world evidence and health economics outcomes research), and a Genomics Research Program anchored by the My Reason® registry, which has enrolled over 35,000 participants with a stated target of 50,000 and is being commercialized through Nephronomics, a precision medicine company co-founded with Fresenius Medical Care. Recent strategic activity includes a 2026 joint venture with Central Nephrology Clinic in Jackson, Mississippi and a 2025 strategic collaboration with Nephronomics and GENEWIZ by Azenta Life Sciences for genomic sequencing and analysis.

The business model is B2B professional services with quote-based pricing. Revenue derives from site management fees for clinical trials, data analytics and licensing fees for retrospective and HEOR studies, and genomics research collaborations. The primary customer segment is enterprise pharmaceutical and biotech sponsors conducting renal and CKM trials; CSL Vifor is a disclosed named customer for the data analytics line. GTM is sales-led with direct enterprise outreach, complemented by conference participation (ASN Kidney Week, ACRP, SCOPE Summit, ERA Congress, among others) and a corporate web presence. Leadership includes President Jan Walter, Global CMO Frank Maddux (Fresenius Medical Care Management Board), VP Global Data Analytics Hans-Jürgen Arens, and Executive Director of F1RST UP® Operations Robin Surane.

Name

Frenova Renal Research

Legal name

Fresenius Medical Care Holdings, Inc.

Website

https://frenova.com

Company type

Private

Founded year

2008

Operating status

Operating

Headcount range

101–250 employees

Short description

Frenova Renal Research is a global Site Management Organization (SMO) and subsidiary of Fresenius Medical Care that manages renal and cardio-kidney-metabolic clinical trials for pharmaceutical and biotech sponsors, leveraging a 2M+ patient longitudinal database, F1RST UP® site network, and My Reason® genomics registry.

Ownership category

akta.pro rank

Product category

Clinical Research Services (Site Management Organization)

NAICS

Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Site Network Operators & SMOs (HLAGACAA)

Keywords

• Clinical research services
• Site management organization
• Nephrology clinical trials
• Renal research
• Real-world evidence analytics

Headquarters

HQ city

Waltham

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Site Management Services: Provides site management services for clinical trials, managing site operations, patient recruitment, and enrollment for third-party pharmaceutical sponsors conducting renal and cardio-kidney-metabolic trials.
2. Data Analytics and Licensing: Offers data analytics services and licensing access to their longitudinal patient database and real-world evidence capabilities for retrospective studies and health economics outcomes research (HEOR).
3. Genomics Research Program: Genomic sequencing and analysis services through strategic collaborations for precision medicine research in kidney disease.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Frenova is a global Site Management Organization (SMO) that manages and executes third-party clinical trials for pharmaceutical and biotech sponsors, specializing in cardio-kidney-metabolic (CKM) therapeutic areas. It delivers site management services through its F1RST UP® US site network and broader Global Network Sites, data analytics and licensing leveraging a 2M+ patient longitudinal database, and a kidney-focused genomics research program (My Reason®) with over 35,000 enrolled participants.

Product overview

Frenova is a global Site Management Organization (SMO) dedicated to managing and executing third-party clinical trials across cardio-kidney-metabolic (CKM) therapeutic areas. The company operates as a unified platform offering three interconnected core services: Site Management (leveraging its F1RST UP® US network and broader Global Network Sites), Data Analytics & Licensing (accessing one of nephrology's largest longitudinal databases spanning 2M+ patients over 25+ years), and a Genomics Research Program anchored by the My Reason® registry. Frenova's relationship with parent company Fresenius Medical Care provides unique access to hundreds of thousands of ESKD and CKD patients worldwide, enabling technology-assisted screening and enrollment alongside data-driven clinical insights.

Differentiator

Problem solved

Functional benefit

Brands

• F1RST UP®: A network of research sites in the US designed to accelerate study feasibility, IRB submission process, budgeting, contracting, and patient screening and enrollment. Part of Frenova's site management services.
• My Reason®

Products and services

• Site Management End-to-end clinical trial site management service providing a network of research sites and clinical project managers to support efficient trial operations, enrollment, and direct communication throughout the life of a clinical trial for pharmaceutical and biotech sponsors.
• Data Analytics & Licensing
• Genomics Research Program
• F1RST UP®
• U.S. Network Sites
• Global Network Sites

Quantifiable outcome

• More than 35,000 participants enrolled in My Reason® genomics research program, with goal of 50,000 participants
• +1 more outcomes

Named customers1 record

Segments2 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Four partnerships are on record, tiered core.

• Central Nephrology Clinic, PLLCcoreStrategic or Co-development Partner · 9 June 2026Frenova and Central Nephrology Clinic formed a research joint venture called Frenova Central Nephrology Research Clinic (FCNRC) based in the Jackson, Mississippi area. The partnership strengthens Frenova's clinical research network in cardiovascular, kidney, and metabolic fields and supports expanded research opportunities for patients in the Central Nephrology community. The new site will leverage Frenova's study pipeline, infrastructure, and centralized services for faster study start-up and scalable operations.
• NephronomicscoreStrategic or Co-development Partner · 31 July 2025Nephronomics, a renal precision medicine company co-founded by Fresenius Medical Care, collaborates with Frenova on the My Reason® genomics research program. Nephronomics holds exclusive commercial rights to the My Reason® dataset and is developing the Nephronomics Atlas, a resource of deep clinical and genomic cardio-kidney-metabolic (CKM) disease data. The collaboration aims to leverage AI/ML models to identify novel disease subtypes, protective genetic variants, and therapeutic targets.
• GENEWIZ by Azenta Life SciencescoreTechnology or Integration · 31 July 2025GENEWIZ by Azenta Life Sciences provides genomic sequencing and analysis services for Frenova's My Reason® genomics research program. Azenta applies its validated DNA sequencing technologies and expertise to generate large-scale genomic data from biospecimens collected through Frenova's extensive nephrology research network. Azenta also provides long-term storage of samples through its global biorepository network.
• Fresenius Medical CarecoreOthersFrenova is a Fresenius Medical Care company that operates as a global Site Management Organization (SMO) dedicated to the management and execution of third-party clinical trials. Frenova leverages its relationship with Fresenius Medical Care's global dialysis clinics and partner nephrology practices to provide access to a global site network.

Scale indicators4 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• DaVita Clinical Research: DaVita Clinical Research is the most directly comparable peer: like Frenova, it operates a Site Management Organization leveraging a major dialysis clinic network (DaVita's ~2,600+ U.S. centers) to recruit ESKD/CKD patients and conduct renal clinical trials. It competes head-to-head with Frenova for pharma-sponsored renal trial work.

Broad incumbents

• IQVIA: IQVIA is the world's largest CRO/SMO with broad therapeutic and geographic coverage. While not renal-specialized, it competes for large multi-therapeutic and renal Phase II–IV programs and can bundle site management with full clinical, data, and real-world evidence services.
• ICON plc: ICON is a top-five global CRO offering site management, clinical operations, and data services across therapeutic areas including renal and cardiovascular. It competes with Frenova for sponsor-awarded renal trial work and offers broader portfolio reach.
• Fortrea (formerly Labcorp Drug Development): Fortrea is a major CRO spun out from Labcorp, providing clinical development and site management services across multiple therapeutic areas including nephrology. It competes for full-service and renal-specific trial engagements that might otherwise go to Frenova.
• Thermo Fisher Scientific (PPD): PPD, now part of Thermo Fisher Scientific, is one of the largest global CROs. It provides clinical operations, site management, and patient recruitment capabilities across renal, cardiovascular, and metabolic therapeutic areas, competing for enterprise pharma sponsor awards.
• Medpace: Medpace is a mid-to-large full-service CRO with therapeutic specialization in areas including cardiovascular and metabolic diseases. Its full-service model and reputation for execution compete with Frenova for sponsor-awarded cardio-kidney-metabolic trial work.
• Syneos Health: Syneos Health is a global biopharmaceutical solutions organization offering clinical development and site management services. It competes with Frenova for pharma-sponsored renal and cardiometabolic trial programs through its broad CRO/SMO portfolio.

Emerging players

• Worldwide Clinical Trials: Worldwide Clinical Trials is a mid-size CRO with therapeutic depth in cardiovascular, metabolic, and rare diseases. It is comparable to Frenova in being therapeutically focused rather than broad-line, and competes for similar sponsor relationships in cardio-kidney-metabolic indications.
• CTI Clinical Trial & Consulting Services: CTI is a specialty CRO with strong therapeutic expertise in nephrology and rare diseases. It is a direct therapeutic-area competitor to Frenova, particularly in renal clinical trials, although it does not have Frenova's dialysis-clinic-network-derived patient access advantage.
• Nephronomics: Nephronomics is a renal precision medicine company co-founded by Fresenius Medical Care that holds exclusive commercial rights to Frenova's My Reason® dataset and is building the Nephronomics Atlas. It is both a strategic partner and an adjacent player in the renal genomics and target-discovery space.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/FrenovaResearch
• YouTubeyoutube.com/c/FreseniusMedicalCareNorthAmerica
• Facebookfacebook.com/FreseniusMedicalCareNA
• LinkedInlinkedin.com/company/3665717

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Frenova Renal Research